Millipore Sigma Vibrant Logo
Atención: Nos hemos mudado. Los productos Merck Millipore ya no pueden adquirirse en MerckMillipore.comMás información

341600 Fibrinogen, Fragment D, Human Plasma

Fibrinogen fragment D is a thermolabile native human plasma protein prepared by digestion of purified fibrinogen followed by preparative electrophoresis.

Fibrinogen, Fragment D, Human Plasma: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.
341600
Purchase on Sigma-Aldrich

Descripción

Replacement Information

Products

Número de referenciaEmbalaje Cant./Env.
341600-200UG Ampolla de plást. 200 μg
Description
OverviewNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile core fragment of fibrinogen. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. The D and E fragments have no common antigenic determinants; therefore, no cross-reaction occurs. Reported to increase endothelial membrane permeability to albumin.
Catalogue Number341600
Brand Family Calbiochem®
References
ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
Fisher, E.G., et al. 1991. Haemostasis 21, 141.
Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
Product Information
FormLyophilized
FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
Quality LevelMQ200
Applications
ApplicationFibrinogen fragment D is a thermolabile native human plasma protein prepared by digestion of purified fibrinogen followed by preparative electrophoresis.
Biological Information
Puritysingle band by SDS-PAGE
SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Physicochemical Information
ContaminantsFragment E: ≤1%
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage -20°C
Do not freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Número de referencia GTIN
341600-200UG 04055977195187

Documentation

Fibrinogen, Fragment D, Human Plasma Ficha datos de seguridad (MSDS)

Título

Ficha técnica de seguridad del material (MSDS) 

Fibrinogen, Fragment D, Human Plasma Certificados de análisis

CargoNúmero de lote
341600

Referencias bibliográficas

Visión general referencias
Spraggon, G., et al. 1997. Nature 389, 455.
Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
Fisher, E.G., et al. 1991. Haemostasis 21, 141.
Ge, M., et al. 1991. Am. J. Physiol. 261, L283.
Ficha técnica

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision24-June-2008 RFH
DescriptionNative fibrinogen fragment D from human plasma prepared by plasmin digestion of purified fibrinogen followed by preparative electrophoresis. Thermolabile fragment. Complete proteolysis of a single fibrinogen molecule produces two D and one E fragments. Fragment D has been shown to increase endothelial monolayer permeability and to decrease polymorphonuclear leukocyte adhesion to endothelial cells. The D and E fragments have no common antigenic determinants; therefore, no cross-reactivity occurs.
FormLyophilized
FormulationLyophilized from 400 mM glycine, 150 mM NaCl.
SourcePrepared from plasma that has been shown by certified tests to be negative for HBsAg and for antibodies to HIV and HCV.
Puritysingle band by SDS-PAGE
ContaminantsFragment E: ≤1%
SolubilitySterile distilled H₂O (200 µg/ml)
Storage -20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing reconstitution, aliquot and freeze (-70°C). Stock solutions are stable for up to 4 h at 20°C or for up to 8 h at 4°C or for up to 3 months at -70°C.
Toxicity Standard Handling
ReferencesSpraggon, G., et al. 1997. Nature 389, 455.
Stirk, C.M., et al. 1993. Atherosclerosis 103, 159.
Vogel, P., et al. 1993. Eur. Surg. Res. 25, 83.
Azpiazu, I., and Chapman, D. 1992. Biochim. Biophys. Acta 1119, 268.
Thompson, W.D., et al. 1992. J. Pathol. 168, 47.
Fisher, E.G., et al. 1991. Haemostasis 21, 141.
Ge, M., et al. 1991. Am. J. Physiol. 261, L283.